Tacair, love your posts, but here's a possible small correction.
If the sale prices is $1000 vs. $743 that's a 34% increase in revenue, as you say. But assuming a constant cost of $364 (per DFS), gross margin increases from $379 to $636, or 68%. EBITDA is based on margin, not revenue, so if EBITDA is 68% higher then the SP at 20x EBITDA would be $1.95 per share.
Somebody please check my figures coz now even I am getting excited.
By the way, did anyone notice that the PLS BMX auction which obtained a spot price of $1250/dmt was for only 5.5% spod? We are projecting 5.8%, so that's another premium on top. Hehe.
Figaro
- Forums
- ASX - By Stock
- CXO
- Ann: Stage 1 DFS and Updated Ore Reserves
Ann: Stage 1 DFS and Updated Ore Reserves, page-91
Featured News
Add CXO (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.9¢ |
Change
0.001(0.51%) |
Mkt cap ! $210.0M |
Open | High | Low | Value | Volume |
9.7¢ | 10.3¢ | 9.5¢ | $2.184M | 22.28M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3700 | 9.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.9¢ | 284656 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3045 | 0.098 |
7 | 572755 | 0.097 |
7 | 858322 | 0.096 |
27 | 1677601 | 0.095 |
4 | 508538 | 0.094 |
Price($) | Vol. | No. |
---|---|---|
0.099 | 242927 | 12 |
0.100 | 1065574 | 14 |
0.105 | 5863533 | 36 |
0.110 | 4439029 | 50 |
0.115 | 3573903 | 35 |
Last trade - 14.46pm 18/11/2024 (20 minute delay) ? |
Featured News
CXO (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
SPONSORED BY The Market Online